Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Neoadjuvant Enfortumab Vedotin and Pembrolizumab for the Treatment of Patients with Upper Tract Urothelial Cancer, NEPTUNE Trial

Trial Status: active

This phase II trial tests how well enfortumab vedotin and pembrolizumab works in treating patients with upper-tract urothelial cancer (UTUC) before surgery (neoadjuvant). Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of cancer cells. Enfortumab attaches to a protein called nectin-4 on cancer cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate. Pembrolizumab is part of a group of therapies called checkpoint inhibitors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving enfortumab vedotin and pembrolizumab before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed at the time of surgery in patients with high-grade UTUC.